Price$358.18+90.24 (+33.68%)
2026-04-142026-07-17
News · 26 weeks60+25%
2026-01-252026-07-19
Mix3090d
- Insider14(47%)
- SEC Filings7(23%)
- Other3(10%)
- Analyst3(10%)
- Earnings2(7%)
- Leadership1(3%)
Latest news
25 items- SECWest Pharmaceutical Services Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)
- ANALYSTBNP Paribas Exane initiated coverage on West Pharm with a new price targetBNP Paribas Exane initiated coverage of West Pharm with a rating of Outperform and set a new price target of $447.00
- PRWest to Host Second-Quarter 2026 Conference CallEXTON, Pa., July 7, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release second-quarter 2026 financial results before the market opens on Thursday, July 23, 2026, and will follow with a conference call to discuss the results and business expectations at 8:00 a.m. Eastern Time. The live webcast can be accessed by clicking here. To ask questions on the conference call, participants need to register in advance by clicking here. Registered telephone participants will receive the dial-in number along with a
- INSIDERSEC Form 4 filed by Director Haugen Janet Brutschea4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)
- PRWest Completes Sale and Transfer of the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery SystemEXTON, Pa., July 1, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced the company completed the sale and transfer of the manufacturing and supply rights for SmartDose® 3.5mL On-Body Delivery System and associated facilities. The transaction closed as planned on July 1, 2026. West will continue to develop and manufacture all other versions of SmartDose, including SmartDose® 10mL On-Body Delivery System, adaptive technology for larger volumes.About WestWest Pharmaceutical
- ANALYSTWest Pharm upgraded by Barclays with a new price targetBarclays upgraded West Pharm from Equal Weight to Overweight and set a new price target of $400.00
- ANALYSTWolfe Research resumed coverage on West Pharm with a new price targetWolfe Research resumed coverage of West Pharm with a rating of Outperform and set a new price target of $375.00
- SECWest Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)
- PRWest Appoints Michel Lagarde to be President and Chief Executive OfficerExperienced healthcare and life sciences executive to lead the Company's next phase of growth and innovationEXTON, Pa., June 1, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that its Board of Directors has appointed Michel Lagarde to be President and Chief Executive Officer (CEO) and a member of the Company's Board of Directors starting August 31, 2026. He succeeds Eric M. Green, who will retire from his roles as President, CEO and Board Chair on that date. The Company also announced as part of the CEO transition that the Board has elected Lead Independent Director Robert F. Frie
- SECAmendment: West Pharmaceutical Services Inc. filed SEC Form 8-K: Financial Statements and Exhibits8-K/A - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)
- INSIDERSVP, Proprietary Segment Campbell Shane Alden covered exercise/tax liability with 219 shares and converted options into 770 shares, increasing direct ownership by 881% to 613 units (SEC Form 4)4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)
- SECSEC Form SD filed by West Pharmaceutical Services Inc.SD - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)
- SECWest Pharmaceutical Services Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)
- INSIDERDirector Pucci Paolo was granted 791 shares, increasing direct ownership by 7% to 11,854 units (SEC Form 4)4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)
- INSIDERDirector Michels Douglas A was granted 791 shares, increasing direct ownership by 2% to 46,496 units (SEC Form 4)4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)
- INSIDERDirector Lockhart Stephen H was granted 791 shares, increasing direct ownership by 29% to 3,523 units (SEC Form 4)4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)
- INSIDERDirector Lai Goldman Myla was granted 791 shares, increasing direct ownership by 4% to 20,435 units (SEC Form 4)4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)
- INSIDERDirector Keller Deborah L was granted 791 shares, increasing direct ownership by 7% to 11,560 units (SEC Form 4)4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)
- INSIDERDirector Joseph Molly was granted 791 shares, increasing direct ownership by 22% to 4,398 units (SEC Form 4)4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)
- INSIDERDirector Haugen Janet Brutschea was granted 791 shares, increasing direct ownership by 50% to 2,373 units (SEC Form 4)4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)
- INSIDERDirector Friel Robert F was granted 791 shares, increasing direct ownership by 17% to 5,513 units (SEC Form 4)4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)
- INSIDERDirector Feehery William F was granted 791 shares, increasing direct ownership by 2% to 32,519 units (SEC Form 4)4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)
- INSIDERDirector Buthman Mark A was granted 791 shares, increasing direct ownership by 2% to 44,309 units (SEC Form 4)4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)
- SECWest Pharmaceutical Services Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Filer)
- INSIDERSr. VP & Chief HR Officer Favorite Annette F exercised 2,817 shares at a strike of $83.47 and sold $859,753 worth of shares (2,817 units at $305.20) (SEC Form 4)4 - WEST PHARMACEUTICAL SERVICES INC (0000105770) (Issuer)
WST FAQ
7 questionsWhat does West Pharmaceutical Services Inc. do?
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced...Where does WST stock trade?
West Pharmaceutical Services Inc. (WST) is listed on NYSE.What sector and industry is WST in?
West Pharmaceutical Services Inc. operates in the Health Care sector, Medical/Dental Instruments industry.Does WST pay a dividend?
WST's most recent ex-dividend date was 2026-04-29 with a cash dividend of $0.22 per share. No future ex-date is on file yet.What are analysts saying about WST?
West Pharmaceutical Services Inc. has had 8 recent analyst actions on file. The most recent action was from BNP Paribas Exane: Outperform on 2026-07-13.What companies are similar to WST?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare WST side-by-side with any of them on Quantisnow.How can I track WST on Quantisnow?
Quantisnow aggregates West Pharmaceutical Services Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow WST to receive live email and push alerts on every new disclosure.